Haemato-oncology: High-Quality Care and Access to Innovations
The Ministry of Health of the Russian Federation combined efforts with federal and regional healthcare organizers to achieve significant progress in providing high-quality medical care to patients with haemato-oncological diseases. Haemato-oncology is included in the Oncological Disease Management Federal Programme, national clinical recommendations, treatment protocols and standards are updated. Additionally, a unified digital outline is created to monitor the situation and to forecast the amount of medical care for patients, plus latest generation target drugs are gradually included in restrictive lists. According to leading federal centres and regional experts, in order to significantly increase the access to high-quality medical care for patients with haemato-oncological diseases today, additional focus is needed on the following aspects: increased financing, timely experience exchange among federal and regional experts, teaching regional healthcare experts and organizers the principles resource base usage (working with the digital outline, planning the needed volume of medical care). Also, when choosing the most effective treatment in addition to achieving the best clinical results considerations should include effective expenditure of budget resources.
● What are the perspectives for further improvement of clinical recommendations for treatment of haemato-oncological diseases (using CLL and AML as examples)?
● Is it possible to adjust approaches and principles of budget planning for treatment of patients, once there are target drugs with a fixed course of treatment?
● Has the level of availability of highly effective and innovative (target) treatments been updated since haemato-oncology was included in the Oncological Disease Management Federal Programme? (using CLL as an example)?
● What is in store in terms of organizational innovations in providing high-quality medical care to patients (creating a single management and succession care outline, using CLL as an example)?
● How will increased financing of 14 high-cost ICD codes impact availability of target treatments for patients with haemato-oncological diseases?